Ismail Ozcan, MD
Family Medicine · Baldwin, NYNPI 1932271509
Payments from drug & device makers
Across 94 payments — averaging $29.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$458
- AstraZeneca$349
- Medtronic$308
- Boston Scientific$298
- Novo Nordisk$281
- Galderma Laboratories, L.p.$212
- plus $862 from 17 others
What the payments were for
- Food & beverage$2,73099%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $458 |
| AstraZeneca | 13 | $349 |
| Medtronic | 3 | $308 |
| Boston Scientific | 2 | $298 |
| Novo Nordisk | 15 | $281 |
| Galderma Laboratories, L.p. | 1 | $212 |
| Lilly USA, LLC | 10 | $207 |
| GSK | 6 | $117 |
| Johnson & Johnson | 3 | $82 |
| Pfizer | 3 | $65 |
| Merck | 4 | $65 |
| Lundbeck LLC | 3 | $51 |
| Biomarin Pharmaceutical Inc. | 1 | $47 |
| Dexcom, Inc. | 2 | $45 |
| Cipher Pharmaceuticals US LLC | 1 | $41 |
| Shield Therapeutics Inc | 1 | $24 |
| Bayer | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Novartis | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$158
- APOLLO ESG System$149
- GENERAL VASCULAR INTERVENTION$149
- VenaSeal$138
- AIRSUPRA$125
- BOTOX$108
How this compares
$2,767 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $148,642 |
| MounjaroTirzepatide | 25 | $31,565 |
| EliquisApixaban | 18 | $31,211 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $30,657 |
| JardianceEmpagliflozin | 18 | $27,048 |
| BotoxOnabotulinumtoxina | 13 | $16,994 |
| JanuviaSitagliptin Phosphate | 18 | $16,783 |
| XareltoRivaroxaban | 11 | $16,146 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $7,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,357 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,163 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,421 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,583 |
| Novolog FlexpenInsulin Aspart | 16 | $2,929 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $281 | $148,642107 claims |
| MerckJanumet, Januvia | $65 | $47,44142 claims |
| Lilly USA, LLCMounjaro | $207 | $31,56525 claims |
| PfizerEliquis | $65 | $31,21118 claims |
| AbbVieBotox, Synthroid | $458 | $17,41724 claims |
| Johnson & JohnsonXarelto | $82 | $16,14611 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $117 | $12,52123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Baldwin
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.